These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 14676326)

  • 1. Antitumor efficacy of cytotoxic drugs and the monoclonal antibody 806 is enhanced by the EGF receptor inhibitor AG1478.
    Johns TG; Luwor RB; Murone C; Walker F; Weinstock J; Vitali AA; Perera RM; Jungbluth AA; Stockert E; Old LJ; Nice EC; Burgess AW; Scott AM
    Proc Natl Acad Sci U S A; 2003 Dec; 100(26):15871-6. PubMed ID: 14676326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity.
    Perera RM; Narita Y; Furnari FB; Gan HK; Murone C; Ahlkvist M; Luwor RB; Burgess AW; Stockert E; Jungbluth AA; Old LJ; Cavenee WK; Scott AM; Johns TG
    Clin Cancer Res; 2005 Sep; 11(17):6390-9. PubMed ID: 16144944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human glioblastoma xenografts overexpressing a tumor-specific mutant epidermal growth factor receptor sensitized to cisplatin by the AG1478 tyrosine kinase inhibitor.
    Nagane M; Narita Y; Mishima K; Levitzki A; Burgess AW; Cavenee WK; Huang HJ
    J Neurosurg; 2001 Sep; 95(3):472-9. PubMed ID: 11565870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR.
    Luwor RB; Johns TG; Murone C; Huang HJ; Cavenee WK; Ritter G; Old LJ; Burgess AW; Scott AM
    Cancer Res; 2001 Jul; 61(14):5355-61. PubMed ID: 11454674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy of epidermal growth factor receptor-specific antibodies against glioma xenografts is influenced by receptor levels, activation status, and heterodimerization.
    Johns TG; Perera RM; Vernes SC; Vitali AA; Cao DX; Cavenee WK; Scott AM; Furnari FB
    Clin Cancer Res; 2007 Mar; 13(6):1911-25. PubMed ID: 17363548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
    Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
    Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.
    Ciardiello F; Caputo R; Bianco R; Damiano V; Pomatico G; De Placido S; Bianco AR; Tortora G
    Clin Cancer Res; 2000 May; 6(5):2053-63. PubMed ID: 10815932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced efficacy of radioimmunotherapy with 90Y-CHX-A''-DTPA-hu3S193 by inhibition of epidermal growth factor receptor (EGFR) signaling with EGFR tyrosine kinase inhibitor AG1478.
    Lee FT; Mountain AJ; Kelly MP; Hall C; Rigopoulos A; Johns TG; Smyth FE; Brechbiel MW; Nice EC; Burgess AW; Scott AM
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7080s-7086s. PubMed ID: 16203806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MAb 806 enhances the efficacy of ionizing radiation in glioma xenografts expressing the de2-7 epidermal growth factor receptor.
    Johns TG; McKay MJ; Cvrljevic AN; Gan HK; Taylor C; Xu H; Smyth FE; Scott AM
    Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):572-8. PubMed ID: 20638193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of epidermal growth factor receptor inhibitor alone and in combination with cisplatin on growth of vulvar cancer cells.
    Kim SH; Song YC; Kim SH; Jo H; Song YS
    Ann N Y Acad Sci; 2009 Aug; 1171():642-8. PubMed ID: 19723115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis.
    Zhou Y; Li S; Hu YP; Wang J; Hauser J; Conway AN; Vinci MA; Humphrey L; Zborowska E; Willson JK; Brattain MG
    Cancer Res; 2006 Jan; 66(1):404-11. PubMed ID: 16397255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of combining epidermal growth factor receptor inhibitors and cisplatin on proliferation and apoptosis of oral squamous cell carcinoma cells.
    Takaoka S; Iwase M; Uchida M; Yoshiba S; Kondo G; Watanabe H; Ohashi M; Nagumo M; Shintani S
    Int J Oncol; 2007 Jun; 30(6):1469-76. PubMed ID: 17487368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225.
    Ciardiello F; Bianco R; Damiano V; De Lorenzo S; Pepe S; De Placido S; Fan Z; Mendelsohn J; Bianco AR; Tortora G
    Clin Cancer Res; 1999 Apr; 5(4):909-16. PubMed ID: 10213228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice.
    Pollack VA; Savage DM; Baker DA; Tsaparikos KE; Sloan DE; Moyer JD; Barbacci EG; Pustilnik LR; Smolarek TA; Davis JA; Vaidya MP; Arnold LD; Doty JL; Iwata KK; Morin MJ
    J Pharmacol Exp Ther; 1999 Nov; 291(2):739-48. PubMed ID: 10525095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical analysis of the analinoquinazoline AG1478, a specific small molecule inhibitor of EGF receptor tyrosine kinase.
    Ellis AG; Doherty MM; Walker F; Weinstock J; Nerrie M; Vitali A; Murphy R; Johns TG; Scott AM; Levitzki A; McLachlan G; Webster LK; Burgess AW; Nice EC
    Biochem Pharmacol; 2006 May; 71(10):1422-34. PubMed ID: 16522318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors.
    Rewcastle GW; Murray DK; Elliott WL; Fry DW; Howard CT; Nelson JM; Roberts BJ; Vincent PW; Showalter HD; Winters RT; Denny WA
    J Med Chem; 1998 Feb; 41(5):742-51. PubMed ID: 9513602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anticancer efficacy of the irreversible EGFr tyrosine kinase inhibitor PD 0169414 against human tumor xenografts.
    Vincent PW; Bridges AJ; Dykes DJ; Fry DW; Leopold WR; Patmore SJ; Roberts BJ; Rose S; Sherwood V; Zhou H; Elliott WL
    Cancer Chemother Pharmacol; 2000; 45(3):231-8. PubMed ID: 10663641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.
    Sok JC; Coppelli FM; Thomas SM; Lango MN; Xi S; Hunt JL; Freilino ML; Graner MW; Wikstrand CJ; Bigner DD; Gooding WE; Furnari FB; Grandis JR
    Clin Cancer Res; 2006 Sep; 12(17):5064-73. PubMed ID: 16951222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tyrosine kinase inhibitors. 13. Structure-activity relationships for soluble 7-substituted 4-[(3-bromophenyl)amino]pyrido[4,3-d]pyrimidines designed as inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor.
    Thompson AM; Murray DK; Elliott WL; Fry DW; Nelson JA; Showalter HD; Roberts BJ; Vincent PW; Denny WA
    J Med Chem; 1997 Nov; 40(24):3915-25. PubMed ID: 9397172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of HNSCC cell lines with the EGFR-specific inhibitor cetuximab (Erbitux) results in paradox phosphorylation of tyrosine 1173 in the receptor.
    Mandic R; Rodgarkia-Dara CJ; Zhu L; Folz BJ; Bette M; Weihe E; Neubauer A; Werner JA
    FEBS Lett; 2006 Sep; 580(20):4793-800. PubMed ID: 16904111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.